Navigation Links
High-Efficiency Transfections Achieved with New Low-Toxicity Reagent


Nonliposomal formulation yields high efficiencies in a variety of transfection conditions

Brenda Rogers Paul Kotturi Natalia Novoradovskaya
Stratagene

Introducing foreign DNA into eukaryotic cells requires high-potency transfections, which demand superior quality transfection reagents that are efficient, have low toxicity, and work in the presence or absence of serum. We compared Stratagenes new GeneJammer transfection reagent to each of five leading transfection reagents. GeneJammer reagent, a new nonliposomal formulation, not only performed well in numerous cell lines, it also yielded high efficiencies in primary cells. When the viability of transfected cells was evaluated, GeneJammer reagent showed the highest number of living transfectants for all cell lines tested.

The demand for high-efficiency transfections is increasing, reflecting the expanding applications for transfection technology. Introducing foreign DNA into eukaryotic cells has become fundamental to analyzing gene function, producing recombinant gene products, and devising strategies for gene therapy. Successful transfection results rely on the transfection method and the capability of the transfection reagent.1,2,3 The ideal transfection reagent is characterized by specific attributes, such as high efficiency in a wide variety of cells in the presence or absence of serum and the inclusion of antibiotics, growth factors, or other supplements. Other important attributes include low toxicity, high stability, and easy handling.

Stratagenes new GeneJammer transfection reagent, which is a proprietary formulation of a polyamine and other components, offers these essential qualitites for achieving successful transfection results. We subjected GeneJammer reagent and five of the most popular transfection reagents to extensive analyses, comparing transfection perform
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors
2. Streamline Your siRNA Transfections
3. 140-Fold Increase of Protein Achieved in Pichia Fermentation
4. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
5. Brilliant Core Reagent Kits for QPCR and QRT-PCR
6. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
7. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
8. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
9. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
10. TransMessenger Transfection Reagent
11. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures

Post Your Comments:
(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...
(Date:11/5/2009)...RDOVA, Calif., Nov. 5 Th...lier of innovative products for processing and sto...the first quarter of fiscal 2010. ,, For the qu...ed revenues of $5.2 million, a 15 percent increase...r a year ago. The Company said the key contributor...
(Date:11/5/2009)..., Calif., Nov. 5 Cepheid...ves will be speaking at the following investor con... webcast. , , Credit Suisse Health...sday, 12 November, 2009 at 10 a.m. Mountain Time,... London, England, Tuesday, 1 Decem...
(Date:11/5/2009)...exas, Nov. 5 SpineSmith Partners h... to co-develop a unique scaffold that mimics the s...aluation of several commercial products by SpineSm...pany believes the GenOsteo scaffold represents a s...a unique and ideal environment for the delivery of...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Cepheid to Webcast Upcoming Financial Presentations 2SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2
...SAN DIEGO, March 2 BioMed Realty Trust, Inc. (NYS...cutive management will present at the Citi 2009 Gl... approximately 9:05 a.m. Eastern Standard Time on ...ll be open to all investors by calling 719.785.559...ioMed Realty Trust , BioMed Realty Trust, Inc. is...
..., Innovative B.C. Technology Promises to Revolu...ER, March 2 /PRNewswire-FirstCall/ - EnWave Corpor...ay announced that it has completed the first sale ...uipment to CAL-SAN Enterprises, Ltd. of Richmond, ...producers. With this sale, EnWave has proven that ...
... EXTON, Pa., March 2 Morphotek(R), Inc., a sub...ay announced that it has commenced a,multi-centere...ody in,mesothelioma. The study will evaluate MORAb...isplatinum, as a first-line treatment for patients... the study is to assess the efficacy of MORAb-009,...
Other Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3
(Date:11/4/2009)...an has received more than $10 million in research ...ederal stimulus program, bringing thetotal amount ...$23 million. Thirty-three projects achieved stimu...o weather. , "The university has thoughtfully un... scholarly excellence to federal agency priorities...
(Date:11/4/2009)...re/ -- What,s the cost of saving a teenage life? W...ing from prescription medication abuse, there,s no... may be unaware that the lock-boxes they,ve instal...g timebomb of prescription drugs. That,s why MEDNE...l supplies, has formed an exclusive partnership wi...
(Date:11/4/2009)...wswire/ -- GenVault Corporation (Carlsbad, CA) tod...joined its Board of Directors. Dr. Brody, the Irw..., is an acclaimed physician-scientist and universi...r. Brody served as president of The Johns Hopkins ...y of Engineering and the Institute of Medicine, an...
Breaking Biology News(10 mins):OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Hormone therapy may confer more aggressive properties to prostate tumors 48453 1Drugs against winter vomiting disease one step closer 48451 1Drugs against winter vomiting disease one step closer 48451 2New Jefferson study may redefine how a chronic auto immune disease is diagnosed 48449 1New Jefferson study may redefine how a chronic auto immune disease is diagnosed 48449 2
...immune system cells go through a laboratory versio...against HIV, believe University of Pittsburgh rese... development of a novel therapeutic vaccine loaded...hich have been galvanized to rally other cells of ...that individual. , At the XVI International AIDS ...
... the Harvard Department of Ophthalmology,s Schepen... Ear Infirmary (MEEI) are the first to learn why t... blood vessels--a unique phenomenon that makes vis... unexpected presence of large amounts of the prote...eptor-3) on the top epithelial layer of normal hea...
...e has its place and role in the oceans ?even the s... lead to more accurate models of ocean change. , ...que biological niche for most animals and plants ?...dolphin. , Bacteria instead have been relegated ... which few species are considered unique, said Jed...
Other Biology News:T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 2T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 3Scientists discover why cornea is transparent and free of blood vessels, allowing vision 2Scientists discover why cornea is transparent and free of blood vessels, allowing vision 3Bacteria can help predict ocean change 2
Mouse Anti-Human E1A (adenovirus early region 1) Monoclonal Antibody, Unconjugated, Clone M73 from Exalpha Biologicals, Inc.
Blocking Reagent, TBS with 1% BSA from Bethyl Laboratories
Anti-Presenilin-1, N-terminus Polyclonal Antibody, Unconjugated from CHEMICON
RayBio Human Chemokine Antibody Array I & 1.1 Service from Raybiotech, Inc.
Biology Products: